Henry Okodaso

Dr. Henry Okodaso


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2025
Verified
Book Chapter
Open access
PDF file
STShellon Thomas
Shellon Thomas
HOHenry Okodaso
Henry Okodaso
KKKush Kanjia
Kush Kanjia
VKVaidehi Khatu
Vaidehi Khatu
DMDervens Kidder Michaud
Dervens Kidder Michaud
Felicia Adaobi IkoloFelicia Adaobi Ikolo
Felicia Adaobi Ikolo
Hemoglobinopathies such as sickle cell disease (SCD) and beta (β)-thalassemia are inherited disorders characterized by defective or insufficient β-globin chain production, resulting in chronic anemia, multi-organ damage, and reduced life expectancy. Affecting millions worldwide, particularly in sub-Saharan Africa, the Mediterranean, South Asia, the Middle East, and the Caribbean, these conditions represent the most common monogenic diseases globally. Traditional treatments, including blood transfusions and hydroxyurea, offer limited long-term benefit, while allogeneic bone marrow transplantation is curative but constrained by donor availability and procedural risks. In recent years, gene therapy and genome editing technologies have emerged as transformative tools, offering the potential for durable, patient-specific cures. This chapter reviews the underlying molecular mechanisms of SCD and β-thalassemia and explores current gene therapy approaches, including lentiviral gene addition and CRISPR-Cas9-mediated editing. A major focus is on reactivation of fetal hemoglobin (HbF) through targeted disruption of transcriptional repressors such as BCL11A. Clinical trial outcomes are examined alongside European Union (EU), United States of America (USA), and United Kingdom (UK) approved therapies such as Casgevy, Lyfgenia, and Zynteglo, highlighting both the therapeutic promise and real-world challenges, including myeloablative toxicity, access disparities, and infrastructure limitations. The chapter also emphasizes the global dimension of hemoglobinopathies and the urgent need for equitable implementation strategies, especially in resource-limited settings. Integrating insights from molecular genetics, clinical research, and global health policy, this chapter provides a comprehensive and up-to-date synthesis of genome editing advances and their application in curing SCD and β-thalassemia.

27 July 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
KSKanwarjot Singh
Kanwarjot Singh
DMDervens Kidder Michaud
Dervens Kidder Michaud
TPTal Parness
Tal Parness
OMOdinaka Emmanuel Mgbeke
Odinaka Emmanuel Mgbeke
HOHenry Okodaso
Henry Okodaso
Felicia Adaobi IkoloFelicia Adaobi Ikolo
Felicia Adaobi Ikolo
Sickle cell disease (SCD) is a monogenic hemoglobinopathy in which hemoglobin S (HbS) polymerizes on deoxygenation, leading to sickling of red blood cells (RBCs) and driving the acute vaso-occlusive crisis (VOC). With curative (transformative) therapies inaccessible to most patients in sub-Saharan Africa and the Caribbean, where burden is highest, optimizing acute VOC care is a priority; yet oxygen is given reactively, after hypoxemia is documented, not at symptom onset when polymerization is most interruptible. We conducted a structured narrative review integrating HbS polymerization kinetics, clinical studies of oxygen-based therapies, trial protocols, and home-care implementation evidence (PubMed, Scopus, Google Scholar; 1974–2026). When RBCs release oxygen, HbS does not solidify at once: a brief pause, the nucleation delay phase (tD), precedes polymerization and sickling. Because tD falls steeply as deoxygenated hemoglobin rises (inversely, to its ~30th–50th power), a small early gain in oxygen saturation (~5–10%) lengthens it many-fold, opening a short window, roughly 30 min from onset, during which oxygen may abort a crisis. The clinical message is that timing, not dose, is decisive: oxygen at the first symptoms may prevent a crisis that the same oxygen, given later, cannot. Standard, high-flow, hyperbaric, and inhaled nitric-oxide modalities help in selected hospital settings, and the DREPADOM model shows community delivery before hospital arrival is feasible and safe. The central argument is precision in timing, not quantity: starting oxygen at symptom onset could turn a low-cost, universally available treatment into a crisis-aborting one for patients beyond the reach of curative therapy. We advance this as a mechanistically grounded but clinically untested hypothesis; regional implementation trials in the Caribbean and sub-Saharan Africa are urgently warranted.